Trial reportPloS one2015
Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease.
Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Changes in bone biomarkers in response to different dosing regimens of cholecalciferol supplementation in children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2023Trial
- Bone turnover markers in the management of CKD-associated osteoporosis-a European consensus.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- Evidence-Based Guidelines for the Diagnosis and Treatment of Pediatric CKD-Mineral and Bone Disorder (Version 2024).Kidney international reports · 2026Article
- Executive Summary of Evidence-Based Guidelines for the Diagnosis and Treatment of Pediatric CKD-Mineral and Bone Disorder (Version 2024).Kidney international reports · 2026Article
- Exhaled breath metabolites reveal postmenopausal gut-bone cross-talk and non-invasive markers for osteoporosis.Communications medicine · 2024Article
- Growth hormone in pediatric chronic kidney disease: more than just height.Pediatric nephrology (Berlin, Germany) · 2024Review
- Chronic kidney disease mineral bone disorder in childhood and young adulthood: a 'growing' understanding.Pediatric nephrology (Berlin, Germany) · 2024Article
- Muscle-bone axis in children with chronic kidney disease: current knowledge and future perspectives.Pediatric nephrology (Berlin, Germany) · 2021Review
- Hemodiafiltration Is Associated With Reduced Inflammation and Increased Bone Formation Compared With Conventional Hemodialysis in Children: The HDF, Hearts and Heights (3H) Study.Kidney international reports · 2021Article
- Vitamin D and Glomerulonephritis.Medicina (Kaunas, Lithuania) · 2021Review
- An innovative and cost-effective way to estimate alkaline phosphatase activity inInternational journal of biochemistry and molecular biology · 2021Article
- Serum and Urinary Osteocalcin in Healthy 7- to 19-Year-Old Finnish Children and Adolescents.Frontiers in pediatrics · 2021Article
- Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?Pediatric nephrology (Berlin, Germany) · 2020Review
- Serum indoxyl sulfate concentrations associate with progression of chronic kidney disease in children.PloS one · 2020Observational
- Strategies for Optimizing Growth in Children With Chronic Kidney Disease.Frontiers in pediatrics · 2020Review
- Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2019Observational
- Management of bone disease in cystinosis: Statement from an international conference.Journal of inherited metabolic disease · 2019Article
- C-type natriuretic peptide attenuates renal osteodystrophy through inhibition of FGF-23/MAPK signaling.Experimental & molecular medicine · 2019Article
- Cardiovascular risk in children and adolescents with end stage renal disease.Clinics (Sao Paulo, Brazil) · 2019Article
- Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.Paediatric drugs · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 20 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe extent and relevance of altered bone metabolism for statural growth in children with chronic kidney disease is controversial. We analyzed the impact of renal dysfunction and recombinant growth hormone therapy on a panel of serum markers of bone metabolism in a large pediatric chronic kidney disease cohort.
methodsBone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRAP5b), sclerostin and C-terminal FGF-23 (cFGF23) normalized for age and sex were analyzed in 556 children aged 6-18 years with an estimated glomerular filtration rate (eGFR) of 10-60 ml/min/1.73 m2. 41 children receiving recombinant growth hormone therapy were compared to an untreated matched control group.
resultsStandardized levels of BAP, TRAP5b and cFGF-23 were increased whereas sclerostin was reduced. BAP was correlated positively and cFGF-23 inversely with eGFR. Intact serum parathormone was an independent positive predictor of BAP and TRAP5b and negatively associated with sclerostin. BAP and TRAP5B were negatively affected by increased C-reactive protein levels. In children receiving recombinant growth hormone, BAP was higher and TRAP5b lower than in untreated controls. Sclerostin levels were in the normal range and higher than in untreated controls. Serum sclerostin and cFGF-23 independently predicted height standard deviation score, and BAP and TRAP5b the prospective change in height standard deviation score.
conclusionMarkers of bone metabolism indicate a high-bone turnover state in children with chronic kidney disease. Growth hormone induces an osteoanabolic pattern and normalizes osteocyte activity. The osteocyte markers cFGF23 and sclerostin are associated with standardized height, and the markers of bone turnover predict height velocity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.